Navigation Links
Medivir Announces TMC435 in an Expanded Clinical Collaboration
Date:4/18/2012

C435, a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialisation of TMC435 in the Nordic markets, once approved.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®, was launched on the US market in 2011. Xerese®/Xerclear®, which has been approved in both the US and Europe, is being launched in collaboration with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company's website: http://www.medivir.com

For more information about Medivir, please contact:

Medivir
Rein Piir, EVP Corporate Affairs & IR    
Mobile: +46-708-537-292 

M:Communications
Europe: Mary-Jane Elliott, Amber Bielecka, Hollie Vile    
medivir@mcomgroup.com
+44(0)20-7920-2330



'/>"/>
SOURCE Medivir
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivir: R&D Day
2. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
3. CardioInsight Announces Appointment of Jim Bullock as Chairman of the Board of Directors
4. WaferGen Bio-systems Announces Open Format qPCR Platform and Strategic Realignment
5. Custom Spine Announces 510K Clearance for Securis Cannulated Screw System
6. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
7. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
8. ADVENTRX Announces Establishment of Regulatory Advisory Board
9. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
10. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
11. GenVec Announces Research on Improved Vaccine Vectors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Grace Century, ... and healthcare projects, announces the addition of Dr. ... to its advisory team. Dr. Siddiqui will provide further ... , A graduate of University College Medical School ... degreed in medicine in 2001. With further certification as ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... Oct. 22, 2014 Research and Markets ... Market by Material, by Application, Geography - Global Analysis ... offering. Organic electronics, also called as ... material science which deals with small conductive molecules and ... small molecules and polymers are carbon based, made using ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... may be on the rise, but solar cells are ... collect. Under the direction of a new professor at ... researchers have developed a new material that absorbs a ... efficient and less expensive solar technology. A paper ...
... a market leader in business transformation consulting, has appointed ... and Health Care Practice Group. In his new role, ... the Health Care and Life Science industry and be ... service offerings concentrating on alignment of organizational operations with ...
... In preparation for its European launch of Benlysta, the ... Genome Sciences (HGS) needed a customer relationship management (CRM) ... team. The company had a long list of selection ... speed, and low system maintenance. Veeva CRM - the ...
Cached Biology Technology:Solar power could get boost from new light absorption design 2Axia Value Chain Appoints John Christina Managing Director of Life Sciences Practice 2Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment 2Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment 3
(Date:10/25/2014)... This report covers the specifics of microRNA (miRNA) as ... of research due to its versatility and stability, properties ... components. miRNA,s non-coding nature and ability to affect genetic ... a biomarker for a variety of diseases. This prompted ... advancement in therapeutic development. Furthermore there are a number ...
(Date:10/22/2014)... Oct. 20, 2014  Leading identity analyst firm Acuity ... of the world,s population will have a chip-based National ... Europe . Asia , with ... accounting for more than 60% of all National eID ... report  -- "The Global National eID Industry ...
(Date:10/18/2014)... patients with undiagnosed, suspected genetic conditions, a certain type ... molecular diagnostic yield than traditional molecular diagnostic methods, according ... study is being released to coincide with the American ... which sequences the protein­coding region of the genome (the ... a cell or organism), has been rapidly applied in ...
Breaking Biology News(10 mins):MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... Researchers from the Polytechnic Institute of New York University ... National Institutes of Health (NIH) to further a novel ... cancer and diabetes. Jin Kim Montclare, associate ... Yingkai Zhang, associate professor of chemistry at NYU, have ...
... and Oxford, UK An advanced tumor is a complex ... it grows until it contains several subspecies of cells that ... heterogeneity is what makes advanced tumors so difficult to treat. ... Cell , an international team of scientists led jointly by ...
... now offering two more language-specific eBook collections, in French ... 330 titles, and the Italian collection offers over 400 ... aim to address the needs of the French- and ... accessing relevant scientific content from medicine, mathematics, computer science ...
Cached Biology News:National Institutes of Health to fund research probing proteins linked to cancer, diabetes 2Herding cancer cells to their death 2Herding cancer cells to their death 3Springer launches French- and Italian-language eBook collections 2